Comparison of TTV viral load in healthy volunteers and melanoma patients before and after 6 months of anti-PD-1 therapy.

(A) Torque Teno Virus (TTV) viral load of healthy volunteers (HV) and melanoma patients prior to the initiation of anti-PD-1 therapy (V1). (B) and (C) TTV viral load in the treatment-sensitive tumor and treatment-resistant tumor groups of melanoma patients B) before (V1) and C) 6 months after (V2) the initiation of anti-PD-1 therapy. (D) TTV viral load of the melanoma patients prior to the initiation of anti-PD-1 therapy (V1) and after 6 months of anti-PD-1 therapy (V2). A viral load of 0.45 log10 copy/mL as assigned to patients and controls with undetectable viral load which is the lowest limit of detection. ns: non-significant.